British Dragon Orals
Stanozolol can stimulate the production of prostaglandin E2 and the matrix metalloproteases collagenase and stromelysin in skin fibroblasts. It has been found to inhibit growth factor-stimulated DNA synthesis and fibroblasts.
Winstrol has substantial fibrinolytic properties and has been effective in the treatment of urticaria, Raynaud’s phenomenon, cryptofibrinogenemia, and lipodermatosclerosis. Stanozolol has also effected cures of osteonecrosis in cases resistant to all other therapy. British Dragon Orals
Stanozolol has been used successfully in the treatment of AIDS wasting syndrome.
Winstrol is also useful in the treatment of hereditary angioedema. It is somewhat hepatotoxic but less so than many other oral anabolic steroids. It influences some immunological processes.
Stanozolol has been found to increase lymphocyte count and CD8+ cell numbers, but to decrease CD4+ and CD3+ in postmenopausal women using it for osteoporosis. This effect would plausibly be useful for the treatment of autoimmune disorders.
Winstrol also lowers lipoprotein (a).
Stanozolol is the chemical name of the active ingredient in Winstrol. Winstrol is a registered trademark of Sanofi-Synthelabo Inc. in the United States and/or other countries. Sanofi has licensed rights of Winstrol to Ovation Pharmaceuticals. (British Dragon Orals)